INTRAGASTRIC BALLOON MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Intragastric Balloon Market Size and Forecast – 2025 to 2032

Intragastric Balloon Market is estimated to be valued at USD 175.7 Mn in 2025 and is expected to reach USD 335.9 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032.

Key Takeaways

• Based on Product Type, the Single Balloon segment leads the market holding an estimated share of 35% in 2025, due to its simplicity and effectiveness in inducing weight loss.
• Based on Filling Material, the Saline Filled segment is projected to dominate with the largest share of the market in 2025, due to its proven effectiveness.
• Based on End User, the Hospital segment is expected to lead the market with a dominating share in 2025, owing the high procedure volume at hospitals.
• Based on Distribution Channel, the Hospital Pharmacies segment is projected to lead the market with largest shares in 2025, supported by the safe and effective medicines provided as hospital settings
• Based on Region, North America is estimated to lead the market with a share of 50% in 2025, owing to its high prevalence of obesity. While, Europe is considered to be the fastest growing region during the forecast period due to growing demand for effective and less invasive weight loss solution.

Market Overview

Intragastric balloons are medical devices that are placed in the stomach endoscopically to reduce the stomach capacity and intake. This procedure is mainly used for weight loss in obese patients. Intragastric balloons offer various advantages such as being less invasive, reversible, and requiring shorter hospital stays. The rising prevalence of obesity and associated diseases is driving the growth of the intragastric balloon market. According to the World Obesity Federation prediction, by 2030, over one billion people worldwide will be living a life of obesity, including 1in 5 women and 1 in 7 men. As World Health Organization states in 2025, the obesity prevalence will reach 18% in men and exceed 21% in women.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Role of Artificial Intelligence (AI) in Intragastric Balloons Market

Integration of artificial intelligence into integrated balloon is transforming the weight loss approach by enhancing patient management and potentially improving outcomes. AI-powered solutions are being developed to support IGB therapies, offering personalized guidance and monitoring. AI-powered virtual care platforms such as Allurion’s Iris Platform provides with real-time monitoring of patient progress, analyze data from connected scales and smartwatches and offers personalized behavior change guidance.

In May 2025, Allurion Technologies, Inc., a developer of weight loss therapies with remarkable gross profit margins of 67%, showcased new studies at the European Congress on Obesity in Malaga, Spain, demonstrating significant weight loss and muscle mass preservation using its Allurion Program, which includes a swallowable gastric balloon and a virtual care suite.

End-User Feedback and Unmet Needs in Intragastric Balloons Market

Consumer Behavior

Patients are increasingly favoring intragastric balloons as an alternative to more invasive weight loss procedures like bariatric surgery. This preference is largely driven by the balloon's minimally invasive nature, shorter recovery time, and the fact that it is reversible. Compared to surgical options, intragastric balloons offer a less intimidating and more accessible option for individuals looking to manage obesity without undergoing major surgery.

Before proceeding with treatment, many patients engage in extensive research. They typically seek out information from multiple sources, including medical reviews, patient testimonials, and recommendations from physicians. This behavior highlights the importance of trust and informed decision-making in the patient journey. For instance, patients often prioritize clinics or healthcare providers that offer comprehensive post-procedure support, such as nutritional counseling, which is critical for sustaining weight loss. Such additional services not only help patients manage their weight but also contribute to improving the overall success of the procedure.

Unmet Needs

Physical Discomfort: Many patients experience discomfort after the balloon insertion, with common issues including nausea, vomiting, or acid reflux. These side effects can be severe enough to require medication. For instance, studies have shown that 20–30% of patients report gastric irritation during the first week after the procedure. Although these side effects are often temporary, they can significantly impact the patient’s overall experience.

Temporary Results: One of the major challenges with intragastric balloons is that their weight loss benefits may not be long-lasting without sustained lifestyle changes. After the balloon is removed—usually within 6 to 12 months—many patients regain some or all of the weight they lost, especially if they do not adhere to recommended dietary and exercise routines. A 2022 study indicated that 15–20% of patients regained more than 50% of their lost weight within a year of balloon removal. This highlights the need for effective lifestyle intervention to maintain weight loss beyond the use of the balloon.

Cost Barriers: The cost of the intragastric balloon procedure can be a significant hurdle for many patients, especially in markets like the U.S. where the procedure is often considered elective and not covered by insurance. On average, the procedure can cost between $6,000 and $8,000, which is a considerable out-of-pocket expense for most individuals. This financial barrier limits access for many potential patients and can influence their decision-making process.

Segmental Insights

To learn more about this report, Download Free Sample

Intragastric Balloons Market Insights, By Product Type:  Singe Balloon Dominates the Market Owing to Its Simplicity and Effectiveness in Weight Loss

The single balloon segment is has emerged as the dominant segment in the global intragastric balloon market, capturing the highest share of 35.2% in 2025. The popularity of single ballon procedure is observed due to its minimal invasiveness, outpatient nature, and potential for weight loss. These factors are more effective when combines with lifestyle changes and diet.

To add more to this, the single balloon procedure is a non-surgical weigh loss treatment where a deflated balloon is inserted into the stomach through an endoscope, then inflated with a saline solution. The balloon can be typically removed after few months, usually 6 to 12 months.

According to John Hopkins Medicines, studies have shown that this procedure can lead to significant weight loss with patient potentially losing 10-25 kg.

Intragastric Balloons Market Insights, By Filling Material:  Saline Filling Acquires the Largest Share Owing to its Proven Effectiveness

Saline filling segment has emerged as the dominant segment in the global intragastric balloon market with highest share in 2025. The saline filling helps to fill the stomach and create a feeling of fullness. This aids in weight loss by reducing the amount of food an individual consumes. Once the balloon is inserted with the stomach, the sterile saline solution in added to the ballon, which is also commonly known as saltwater solution.

Intragastric Balloons Market Insights, By End User- Hospital- High Procedure Volume at Hospitals

The hospital segment is expected to show the constant performance of largest share in the market in 2025, owing to the high procedure volume and utilization of advanced equipment and facilities. The hospitals are mostly equipped with necessary endoscopic equipment and post-operative care facilities. Hospitals setting offer immediate access to medical professionals and emergency care. There are at least 50-60 hospitals in India offering intragastric balloon treatment. This in turn is propelling the intragastric balloons market share.

Intragastric Balloons Market Insights, By Distribution Channel: Hospital Pharmacies- Safe and Effective Medicines

The hospital pharmacies segment is expected to capture the largest shares of the intragastric balloons market in 2025. This is attributed to the safe and effective medicines. Hospital pharmacies play a crucial role in intragastric balloon procedures by dispensing the necessary medications such as medicines needs for nausea and pain, ensuring to the patient’s post-procedure care.

Regional Insights

To learn more about this report, Download Free Sample

North America Intragastric Balloons Market Analysis and Trends

North America 

is the largest market for intragastric balloon, accounting for over 

50%

 of the global market share in 2025. This is due to the high prevalence of obesity in the region, as well as the increasing awareness of and demand for minimally invasive weight loss and obesity management procedures. For instance, according to Centers for Disease Control and Prevention, the U.S. obesity prevalence increased from 30.5% to 41.9% from 1999 to 2020. During the same time, the prevalence of severe obesity increased from 4.7% to 9.2%.

Europe Intragastric Balloons Market Analysis and Trends

Europe

 is the second-largest market for intragastric balloon, with a market share of over 

30%

. The market in Europe is expected to grow significantly in the coming years, driven by the rising prevalence of obesity and the increasing availability of intragastric balloon procedures.

United States Intragastric Balloons Market Analysis and Trends

United States is the leading ground for intragastric balloon market. The predominating factor driving the market in this region is the high prevalence of obesity. According to the (WHO) World Health Organization, in 2025, the obesity rate and overweight number is estimated to project about 64% of the U.S. population. Obesity is commonly observed in the low- and middle-incomes class people, experiencing rapid increase. Another factor that contributes to the market growth is the rising demand for minimal invasive weight loss procedures. The U.S. population are seeking for an effective and convenient option for weigh loss. In U.S., the weight loss products and services is a multi-billion-dollar industry. According to the National Institute of Health, one third of Americans are now obese, and 50%-705 are trying to lose weight. This in turn is propelling the intragastric balloons market demand.

France Intragastric Balloons Market Analysis and Trends

In March 2025, Allurion Balloon relaunched in France, roughly half a year after the company suspended its sales amid safety concerns. A recent study cited the prevalence of excess weight and obesity in France at approximately 47% and 17%, respectively. With the current-generation GLP-1s are now available in France, its use will be primarily focused on indicating as a second-line treatment in patients with a body mass index (BMI) of greater than or equal to 35 with careful attention to side effect management. This is further expected to proliferate the intragastric balloons market share.

Intragastric Balloon Market Drivers

Rising prevalence of obesity

Obesity has become a global epidemic, with over 650 million adults worldwide being obese as of 2016. The prevalence of obesity has nearly tripled over the past four decades. Obesity increases the risk of various chronic conditions like heart disease, stroke, type 2 diabetes, hypertension, osteoarthritis, and certain cancers. This is driving the demand for effective long-term weight loss solutions like intragastric balloon. The balloons provide a minimally invasive alternative to tackle obesity. Moreover, according to the WHO data published on March 16, 2023, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. An estimated 46% of adults with hypertension are unaware that they have the condition.

Intragastric Balloon Market Opportunities

Increasing use of connected health platforms

The integration of connected health technologies like mobile apps, ingestible sensors, wearables, and virtual care with intragastric balloon can transform obesity management. Companies are collaborating to develop supporting digital health platforms. For instance, Allurion’s Virtual Care Suite provides remote monitoring before and after balloon placement. Such tools allow real-time data collection, improve patient engagement, and compliance. Their adoption can improve weight loss outcomes.

Increasing medical tourism for obesity treatment

Rise of medical tourism provides opportunities for weight loss balloon manufacturers. Cost advantage, minimal waiting times, and availability of improved healthcare services are attracting patients from developed countries to travel for the procedure. Companies are expanding their footprint in top medical tourism destinations like India, Mexico, Thailand, and Malaysia. Partnerships with hospitals and surgeons catering to medical tourists will help drive the market growth.

Market Report Scope

Intragastric Balloon Market Report Coverage

Analyst Opinion

• The intragastric balloon market is positioned to benefit from the global obesity epidemic, which is accelerating demand for non-surgical weight loss options. According to the World Health Organization (WHO), over 650 million adults worldwide were classified as obese in 2016, and this number is expected to increase significantly. This demographic, paired with growing awareness of non-surgical weight loss solutions, is fueling the intragastric balloons market demand.
• Despite its minimally invasive nature, the intragastric balloon is not without its drawbacks. The issue of physical discomfort remains a significant pain point, with 20–30% of patients experiencing gastric irritation, nausea, and vomiting in the first week post-procedure. A 2022 study published in Obesity Surgery found that 28% of patients required pharmaceutical intervention to manage these symptoms. This data is concerning because such discomfort can lead to a poor patient experience and may result in high dropout rates. Indeed, a significant portion of patients (around 10–15%) either abandon the treatment mid-course or opt for balloon removal earlier than planned due to side effects.
• Furthermore, a study by the American Obesity Association highlighted that while the balloon can lead to average weight loss of 10–15% of total body weight, many patients regain 50% or more of the lost weight within 12 months after balloon removal. This is a fundamental limitation. The key challenge for this market will be to not just address the initial discomfort but also to design balloons that contribute to sustained long-term weight loss. Without effective lifestyle support systems that are integrated into the treatment process, the balloon’s long-term effectiveness will remain limited.

Recent Developments

• In January 2025, Allurion technologies, Inc., a company dedicated to ending obesity, announced Plans to Optimize Muscle Mass During GLP-1 Therapy in Combination with the Allurion Program.
• In January 2025, Allurion Technologies, a company fighting obesity, announced a new clinical study to improve the effectiveness of its weight loss treatment. Allurion stock gained 21% on Wall Street, while it surged around 70% in after-market trading.
• In December 2024, Boston Scientific launched Endoscopic sleeve gastroplasty (ESG) and Intragastric Balloon System (IBS) driven by Apollo and Orbera365 respectively. The launched technology Apollo ESG System is authorized by both US FDA and CDSCO.
• In June 2023, Allurion technologies, a medical device company announced that it has signed a 12-month pilot collaboration agreement with Medtronic, a global leader in medical technology, services, and solutions. Under the terms of their deal, Medtronic will be able to offer Allurion’s swallowable gastric balloon and artificial intelligence-powered Iris healthcare management program through its existing sales channels in Central and Eastern Europe and the Middle East and Africa.

Intragastric Balloon Market Segmentation

• By Product Type
• Single Balloon
• Dual Balloon
• Triple Balloon
• By Filling Material
• Saline Filled
• Gas Filled
• By End User
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• By Distribution Channel
• Online Pharmacies
• Retail Pharmacies
• Hospitals Pharmacies
• By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Top Companies in the Intragastric Balloon Market

• Allurion Technologies
• Allergan (Acquired by Abbott)
• Apollo Endosurgery
• Reshape Medical
• Spatz FGIA
• Endalis
• Silimed
• Medsil
• Districlass médical

Sources

Primary Research Interviews from the following stakeholders

Stakeholders

• Interviews with bariatric surgeons, gastroenterologists, medical device distributors, hospital procurement managers, clinical nutritionists, obesity treatment specialists, and wellness clinic operators across key markets.

Specific stakeholders

• Bariatric and gastroenterology departments in multispecialty hospitals
• Procurement and surgical device leads at private hospitals and specialty clinics
• Clinical research leads in obesity and weight-loss trials at academic medical centers
• Operations managers and patient coordinators at medical tourism agencies
• Product specialists and trainers from intragastric balloon manufacturers
• Nutrition program managers at weight-loss clinics and wellness resorts
• Biomedical engineers and endoscopy unit managers

Databases

• World Health Organization (WHO) Global Health Observatory
• OECD Health Statistics
• National Health and Nutrition Examination Survey (NHANES – U.S.)
• Centers for Disease Control and Prevention (CDC) – Chronic Disease Indicators
• Ministry of Health and Family Welfare (India)
• European Health Interview Survey (EHIS)
• Japan Ministry of Health, Labour and Welfare
• National Institutes of Health (NIH) Clinical Trials Registry
• Australian Institute of Health and Welfare (AIHW)

Magazines

• Bariatric Times
• Medtech Insight
• EndoNurse
• HealthTech Magazine
• The Medical Device Network
• Obesity Medicine News
• DeviceMed
• Gastroenterology & Endoscopy News

Journals

• Obesity Surgery
• Surgical Endoscopy
• World Journal of Gastroenterology
• International Journal of Obesity
• Journal of Obesity & Metabolic Syndrome
• Journal of Gastrointestinal Surgery
• American Journal of Gastroenterology
• Endoscopy International Open

Newspapers

• The Economic Times – Healthcare & Pharmaceuticals
• The Hindu – Health & Wellness
• The Guardian – Health Section
• USA Today – Health and Wellness
• Financial Express – Medical Devices and Health Technology
• Nikkei Asia – Medtech and Wellness Industry
• Business Standard – Healthcare and Hospitals
• South China Morning Post – Health and Lifestyle

Associations

• World Obesity Federation
• International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
• American Society for Metabolic and Bariatric Surgery (ASMBS)
• Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
• Obesity Medicine Association (OMA)
• Indian Association for the Study of Obesity (IASO)
• European Association for the Study of Obesity (EASO)
• Association of Gastrointestinal Endoscopy of India (SGEI)

Public Domain Sources

• U.S. Food and Drug Administration (FDA) – Medical Devices Database
• European Medicines Agency (EMA) – Medical Device Authorizations
• National Institute for Health and Care Excellence (NICE – UK)
• Ministry of Health and Family Welfare (India)
• Directorate General of Health Services (DGHS – India)
• NITI Aayog – Medical Devices Sector Reports
• Department of Pharmaceuticals (India) – MedTech Policy
• Reserve Bank of India (RBI) – Health Sector Investment Reports

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 8 years

*Definition: The intragastric balloon market refers to the industry and market related to intragastric balloon medical devices. Intragastric balloons are soft, fluid-filled balloons that are placed in the stomach through minimally invasive endoscopic procedures. These balloons aid in weight loss by occupying space in the stomach, inducing satiety through neurohormonal signals, and slowing gastric emptying. The global market for intragastric balloon has been growing steadily owing to the rising incidence of obesity and advantages over invasive bariatric surgeries. Key players, new product launches, partnerships, and geographic expansion are shaping the competitive landscape.